Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment
- Autores
- Ceballos, Laura; Alvarez, Luis Ignacio; Moreno Torrejon, Laura; Lanusse, Carlos Edmundo
- Año de publicación
- 2007
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- The altered drug influx/efflux and enhanced metabolic capacity identified in triclabendazole (TCBZ)-resistant Fasciola hepatica contributes to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics (PK) and clinical efficacy (CE) of TCBZ administered alone or co-administered with ivermectin (IVM, drug efflux inhibitor) and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant F. hepatica parasitized sheep. Sheep infected with TCBZ-resistant F. hepatica were divided into three groups (n= 4): untreated control, TCBZ-treated and TCBZ+IVM+MTZ treated sheep. Plasma samples were collected (PK study) and analysed by HPLC. In the CE study, the animals were sacrificed at 15 days post-treatment to evaluate the comparative efficacy against TCBZ-resistant F. hepatica. The presence of IVM and MTZ did not affect the plasma PK behaviour of TCBZ metabolites. The combined drug treatment was not sufficient to enhance the poor efficacy of TCBZ against resistant F. hepatica. Finally, the enhancement of TCBZ concentrations in F. hepatica induced by both IVM and MTZ in ex vivo assays, did not reach a measurable effect under the current in vivo experimental conditions.
Fil: Ceballos, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina
Fil: Alvarez, Luis Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina
Fil: Moreno Torrejon, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina
Fil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina
XXXIX Reunión Anual de la Sociedad Argentina de Farmacología Experimental
Ciudad Autónoma de Buenos Aires
Argentina
Sociedad Argentina de Farmacología Experimental - Materia
-
Triclabendazole
Hepatica
Fasciola
Resistant - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/268501
Ver los metadatos del registro completo
id |
CONICETDig_d10189956fedf2de49f70218e086b6f4 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/268501 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatmentCeballos, LauraAlvarez, Luis IgnacioMoreno Torrejon, LauraLanusse, Carlos EdmundoTriclabendazoleHepaticaFasciolaResistanthttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4The altered drug influx/efflux and enhanced metabolic capacity identified in triclabendazole (TCBZ)-resistant Fasciola hepatica contributes to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics (PK) and clinical efficacy (CE) of TCBZ administered alone or co-administered with ivermectin (IVM, drug efflux inhibitor) and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant F. hepatica parasitized sheep. Sheep infected with TCBZ-resistant F. hepatica were divided into three groups (n= 4): untreated control, TCBZ-treated and TCBZ+IVM+MTZ treated sheep. Plasma samples were collected (PK study) and analysed by HPLC. In the CE study, the animals were sacrificed at 15 days post-treatment to evaluate the comparative efficacy against TCBZ-resistant F. hepatica. The presence of IVM and MTZ did not affect the plasma PK behaviour of TCBZ metabolites. The combined drug treatment was not sufficient to enhance the poor efficacy of TCBZ against resistant F. hepatica. Finally, the enhancement of TCBZ concentrations in F. hepatica induced by both IVM and MTZ in ex vivo assays, did not reach a measurable effect under the current in vivo experimental conditions.Fil: Ceballos, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; ArgentinaFil: Alvarez, Luis Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; ArgentinaFil: Moreno Torrejon, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; ArgentinaFil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; ArgentinaXXXIX Reunión Anual de la Sociedad Argentina de Farmacología ExperimentalCiudad Autónoma de Buenos AiresArgentinaSociedad Argentina de Farmacología ExperimentalSociedad Argentina de Farmacología Experimental2007info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónBookhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/mswordapplication/pdfhttp://hdl.handle.net/11336/268501Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment; XXXIX Reunión Anual de la Sociedad Argentina de Farmacología Experimental; Ciudad Autónoma de Buenos Aires; Argentina; 2007; 64-64CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://aafeargentina.org/congresos-aafe/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:57:30Zoai:ri.conicet.gov.ar:11336/268501instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:57:31.074CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment |
title |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment |
spellingShingle |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment Ceballos, Laura Triclabendazole Hepatica Fasciola Resistant |
title_short |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment |
title_full |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment |
title_fullStr |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment |
title_full_unstemmed |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment |
title_sort |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment |
dc.creator.none.fl_str_mv |
Ceballos, Laura Alvarez, Luis Ignacio Moreno Torrejon, Laura Lanusse, Carlos Edmundo |
author |
Ceballos, Laura |
author_facet |
Ceballos, Laura Alvarez, Luis Ignacio Moreno Torrejon, Laura Lanusse, Carlos Edmundo |
author_role |
author |
author2 |
Alvarez, Luis Ignacio Moreno Torrejon, Laura Lanusse, Carlos Edmundo |
author2_role |
author author author |
dc.subject.none.fl_str_mv |
Triclabendazole Hepatica Fasciola Resistant |
topic |
Triclabendazole Hepatica Fasciola Resistant |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/4.3 https://purl.org/becyt/ford/4 |
dc.description.none.fl_txt_mv |
The altered drug influx/efflux and enhanced metabolic capacity identified in triclabendazole (TCBZ)-resistant Fasciola hepatica contributes to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics (PK) and clinical efficacy (CE) of TCBZ administered alone or co-administered with ivermectin (IVM, drug efflux inhibitor) and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant F. hepatica parasitized sheep. Sheep infected with TCBZ-resistant F. hepatica were divided into three groups (n= 4): untreated control, TCBZ-treated and TCBZ+IVM+MTZ treated sheep. Plasma samples were collected (PK study) and analysed by HPLC. In the CE study, the animals were sacrificed at 15 days post-treatment to evaluate the comparative efficacy against TCBZ-resistant F. hepatica. The presence of IVM and MTZ did not affect the plasma PK behaviour of TCBZ metabolites. The combined drug treatment was not sufficient to enhance the poor efficacy of TCBZ against resistant F. hepatica. Finally, the enhancement of TCBZ concentrations in F. hepatica induced by both IVM and MTZ in ex vivo assays, did not reach a measurable effect under the current in vivo experimental conditions. Fil: Ceballos, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina Fil: Alvarez, Luis Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina Fil: Moreno Torrejon, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina Fil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Facultad de Ciencias Veterinarias. Departamento de Fisiopatología. Laboratorio de Farmacología; Argentina XXXIX Reunión Anual de la Sociedad Argentina de Farmacología Experimental Ciudad Autónoma de Buenos Aires Argentina Sociedad Argentina de Farmacología Experimental |
description |
The altered drug influx/efflux and enhanced metabolic capacity identified in triclabendazole (TCBZ)-resistant Fasciola hepatica contributes to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics (PK) and clinical efficacy (CE) of TCBZ administered alone or co-administered with ivermectin (IVM, drug efflux inhibitor) and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant F. hepatica parasitized sheep. Sheep infected with TCBZ-resistant F. hepatica were divided into three groups (n= 4): untreated control, TCBZ-treated and TCBZ+IVM+MTZ treated sheep. Plasma samples were collected (PK study) and analysed by HPLC. In the CE study, the animals were sacrificed at 15 days post-treatment to evaluate the comparative efficacy against TCBZ-resistant F. hepatica. The presence of IVM and MTZ did not affect the plasma PK behaviour of TCBZ metabolites. The combined drug treatment was not sufficient to enhance the poor efficacy of TCBZ against resistant F. hepatica. Finally, the enhancement of TCBZ concentrations in F. hepatica induced by both IVM and MTZ in ex vivo assays, did not reach a measurable effect under the current in vivo experimental conditions. |
publishDate |
2007 |
dc.date.none.fl_str_mv |
2007 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Reunión Book http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
status_str |
publishedVersion |
format |
conferenceObject |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/268501 Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment; XXXIX Reunión Anual de la Sociedad Argentina de Farmacología Experimental; Ciudad Autónoma de Buenos Aires; Argentina; 2007; 64-64 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/268501 |
identifier_str_mv |
Triclabendazole resistant fasciola hepatica: pharmacokimetic and efficacy assessments of a drug combined treatment; XXXIX Reunión Anual de la Sociedad Argentina de Farmacología Experimental; Ciudad Autónoma de Buenos Aires; Argentina; 2007; 64-64 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://aafeargentina.org/congresos-aafe/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/msword application/pdf |
dc.publisher.none.fl_str_mv |
Sociedad Argentina de Farmacología Experimental |
publisher.none.fl_str_mv |
Sociedad Argentina de Farmacología Experimental |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269466284523520 |
score |
13.13397 |